The weak response of transformed SCLC to PD-L1 inhibitors is comparable to that of EGFR-mutant NSCLC to immunotherapy, suggesting similar biological behavior between transformed SCLC and EGFR-mutant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.